A Lancet editorial calls for "a calmer and more considered approach" in evaluating the safety of rosiglitazone, the subject of a meta-analysis and editorial earlier this week in the New England Journal of Medicine.
The unsigned editorial was released online. It suggests that "the FDA, physicians, and patients can reasonably await the results of RECORD, a phase III trial designed specifically to study cardiovascular outcomes."
Asked to comment, Journal Watch Cardiology Editor-in-Chief Harlan M. Krumholz wrote: "Why would you wait when Avandia has never been shown to avert events or save lives? And now that there is evidence of potential harm — and there are alternative meds — it seems to me that the pressure is on the company to show that it is safe and effective."
read more in the link below:
http://multimedia.thelancet.com/pdf/rosiglitazone_editorial.pdf
No comments:
Post a Comment